Therapeutic Areas

Whether your product exists in a crowded market or is a unique treatment for a rare disease, we have in-house experts and access to key opinion leaders who can provide insights and support your goals every step of the way. Let us custom-build a cross-functional team to transform strategic insights into engaging solutions.

Cardiology

Cardiology encompasses a broad spectrum of conditions, ranging from highly prevalent disorders such as hypertension and coronary artery disease to rare and complex cardiovascular diseases. Given that cardiovascular disease remains the leading cause of death in the United States, comprehensive education around risk factor identification, accurate diagnosis, and evidence-based management is essential. Strengthening knowledge across the continuum of cardiovascular care is critical to improving patient outcomes and reducing the overall burden of disease.

Cell and gene therapy

Cell and gene therapy could fundamentally change how disease is treated by shifting medicine from chronic symptomatic management to precision, potentially curative intervention. The past several years have seen cell and gene therapy move from experimental science to routine, though highly specialized, clinical practice. The American Society of Gene and Cell Therapy reported that, as of Q3 2025, 38 gene therapies and 71 cell therapies had been approved globally, and the pipeline continues to grow, particularly in oncology and rare diseases.

Infectious diseases

The field of infectious diseases continues to evolve from a reactive, pathogen-focused discipline to a more proactive, technology-enabled one driven by advances in genomics, rapid diagnostics, data science and vaccine platforms. At the same time, it is expanding in scope to address emerging and re-emerging threats, antimicrobial resistance, post-infectious syndromes and health equity through closer integration of clinical care, public health, and policy.

Nephrology

More than 1 in 7 adults in the United States are living with chronic kidney disease, with up to 90% unaware that they have the disease, and over 800,000 people living with end-stage disease. Drug development in nephrology offers hope, with a focus on targeted treatments that modify the disease trajectory as opposed to providing supportive care.

Neurology

An analysis of the Global Burden of Disease 2021 study suggests that 1 in 2 Americans has a disease affecting the nervous system, with stroke, Alzheimer's disease and other dementias, diabetic neuropathy, and migraine causing the greatest amount of disability. Over half of rare diseases are believed to have a neurological component. As many neurologic diseases are progressive and are associated with significant disability, researchers are looking to address unmet needs around disease-modifying therapies, early and accurate diagnosis, and equitable access to care.

Oncology

Oncology continues to dominate the drug development pipeline, reflecting both scientific opportunity and unmet clinical need. Rapid advances in precision medicine, immunotherapy, diagnostics, and cell and gene therapies are redefining outcomes in oncology—while the complexity and speed of innovation make ongoing education for clinicians and stakeholders more critical than ever.

Psychiatry

Psychiatric illness affects tens of millions of Americans each year, across all ages, communities, and socioeconomic groups, prompting the CDC to declare that the United States is in a mental health crisis. The combination of high prevalence, rising youth burden, suicide risk, and persistent treatment gaps underscores the urgent need for improved access, innovation, and education in mental health care.

Rare diseases

In the United States, a rare disease is defined as any disorder affecting fewer than 200,000 people. According to the National Organization for Rare Disorders, 10% of Americans live with one of 10,000 known rare diseases, yet only 5% have an FDA-approved treatment. Those living with rare diseases face medical, emotional, and social impact which can be lifelong and extend to entire families, underscoring the importance of improved diagnosis, coordinated care, continued research, education, and policies that support patients and caregivers.

Don't see what you're looking for?

This is just a sampling of our team's diverse experience. And every year we successfully expand into additional therapeutic areas, demonstrating the flexibility and talent of our scientific and strategy teams, as well as the effectiveness and customizability of our approach to medical communication challenges.